AstraZeneca’s Tagrisso plus chemotherapy wins EU approval for NSCLC
05 Jul 2024
Preview
Source: Pharmaceutical Technology
Tagrisso generated $5.8bn in 2023 for AstraZeneca. Credit: rarrarorro via Shutterstock.
AstraZeneca has won approval from the European Commission for Tagrisso (osimertinib) in combination with chemotherapy for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations (EGFRm) in adults.
The tyrosine kinase inhibitor has been approved alongside pemetrexed and platinum-based chemotherapy for the first-line treatment of adults whose tumours have exon 19 deletions or exon 21 (L858R) mutations.
Approval is based on positive data from the Phase III FLAURA2 trial (NCT04035486). The trial enrolled 557 patients, showing that Tagrisso and chemotherapy reduced the risk of disease progression or death by 38% by investigator assessment compared to Tagrisso monotherapy, which is the first-line global standard of care.
Additionally, median progression-free survival was 25.5 months for patients treated with Tagrisso plus chemotherapy, an 8.8-month improvement versus monotherapy.
See Also:CAN-3110 by Candel Therapeutics for High-Grade Glioma: Likelihood of Approval
Preview
Source: Pharmaceutical Technology
ICTCAR-028 by Innovative Cellular Therapeutics for Hematological Tumor: Likelihood of Approval
Preview
Source: Pharmaceutical Technology
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approving Tagrisso last month. The drug earned AstraZeneca $5.8bn in sales last year, as per the company’s financials. According to GlobalData’s Pharma Intelligence Centre, Tagrisso is forecast to generate $7.4bn in 2030.
GlobalData is the parent company of Pharmaceutical Technology.
Currently, AstraZeneca’s Imfinzi (durvalumab) is the standard of care for patients with stage III EGFRm NSCLC, but studies have shown that administering immunotherapy to patients with EGFRm is associated with very low response rates.
In the announcement accompanying the approval, AstraZeneca oncology business executive vice president Dave Fredrickson said: “This approval reinforces Tagrisso as the backbone therapy in EGFR-mutated lung cancer either as monotherapy or in combination with chemotherapy. This is especially important for those with more aggressive disease, including patients whose cancer has spread to the brain and those with L858R mutations.”
Tagrisso combined with chemotherapy is already approved for the first-line treatment of locally advanced or metastatic EGFRm NSCLC in the USA, China, Japan, and other countries. It is also approved as monotherapy in more than 110 countries, including in the USA, EU, China, and Japan, for locally advanced or metastatic EGFRm NSCLC, EGFR T790m positive NSCLC, and as an adjuvant therapy for early-stage EGFRm NSCLC.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.